-
Listing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLees meerSeamless listing, trading, clearing and settlement for fixed income
-
Handelsinformatie
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLees meer
Seamless listing, trading, clearing and settlement for fixed income
-
Clearing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLees meer
Seamless listing, trading, clearing and settlement for fixed income
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLees meerEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Lees meerThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperNext generation of indicesLees meerThis white paper marks the second edition of Euronext’s Index Outlook series, a recurring publication designed to give investors deeper insight into our index innovation agenda and the structural forces shaping global markets.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Lees meerShaping capital markets for future generations
ASIT biotech
11/05/2016
ASIT biotech zet eerste stappen op de Beurs
Euronext Brussel en Parijs hebben vandaag, 11 mei 2016, ASIT Biotech ontvangen, een Belgische vennootschap gespecialiseerd in de behandeling van allergieën. Thierry Legon, CEO van ASIT Biotech, heeft de openingsbel geluid om de eerste notering te vieren van het bedrijf dat 23.5 miljoen heeft opgehaald tijdens deze IPO.ASIT biotech treedt op deze manier toe tot een gemeenschap van 77 bedrijven die gespecialiseerd zijn in life sciences genoteerd op de Euronext markten.